Breaking News Instant updates and real-time market news.

ICPT

Intercept

$98.12

-15.36 (-13.54%)

08:40
09/13/17
09/13
08:40
09/13/17
08:40

Intercept letter doesn't change fundamental view of Ocaliva, says JMP Securities

JMP Securities analyst Liisa Bayko said the warning letter sent by Intercept to health care providers regarding post-marketing reports of liver issues and death in certain PBC patients highlights risks that were already known and doesn't change her fundamental view on Ocaliva. The analyst, who sees little read through to the ongoing Phase 3 REGENERATE trial in NASH patients and views yesterday's drop in Intercept shares as an overreaction, keeps an Outperform rating and $150 price target on the stock.

ICPT Intercept
$98.12

-15.36 (-13.54%)

09/12/17
BARD
09/12/17
NO CHANGE
Target $332
BARD
Outperform
Baird would buy Intercept on weakness
Baird analyst Brian Skorney recommends buying Intercept shares on weakness related to the "Dear Healthcare Provider Letter." The analyst said there is no new information in the letter and serves as a reminder to modify does according to the label for patients with hepatic impairment following cases of Ocaliva being dosed more frequently than recommended. Skorny rates Intercept an Outperform with a $332 price target.
09/13/17
SBSH
09/13/17
NO CHANGE
Target $150
SBSH
Buy
Intercept price target lowered to $150 from $240 at Citi
Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $150 saying a "more robust" competitive landscape in both primary biliary cholangitis and nonalcoholic steatohepatitis could limit peak sales of Ocaliva. While the drug appears to be effective and safe in NASH, its overall profile may "not be strong enough to drive a rapid increase" in the NASH diagnosis rate upon approval, limiting the drug's first mover advantage, Beatty tells investors in a research after the company sent a letter to health care providers warning that serious liver injuries, including death, have been reported in primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. Safety concerns are likely to remain an overhang on the shares at least until results from the Phase 3 Regenerate trial in the first half of 2019, which is beyond the 12 month time horizon of the new target price, Beatty writes. He keeps a Buy rating on Intercept. The stock yesterday closed down 13.5%, or $15.36, to $98.12.
09/13/17
MSCO
09/13/17
NO CHANGE
MSCO
Underweight
Intercept talks raise concern of potentially larger issue, says Morgan Stanley
Morgan Stanley analyst Andrew Berens noted that Intercept attended the firm's healthcare conference and discussed its recently sent "Dear Healthcare Provider" letter regarding liver toxicity seen with Ocaliva in some PBC patients. Discussion at the event suggests Ocaliva may have direct effect on liver toxicity in the presence of cholestasis and/or high drug levels, according to Berens, who sees this issue having significant implications for the drug, especially in NASH patients, he tells investors. Berens keeps an Underweight rating and $75 price target on Intercept shares, which closed yesterday down 13.5% at $98.12.
09/13/17
BMOC
09/13/17
NO CHANGE
BMOC
Intercept should be bought on weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says the letter sent by Intercept to healthcare providers regarding its Ocaliva drug relates to failure by doctors to adhere to dose adjustments recommended in its label. Since no new adverse events were cited in the letter, the analyst does not expect any changes to the label. He continues to expect strong Ocaliva prescriptions to result in the company reporting beat and raise Q3 results, and he recommends buying the stock on weakness. He keeps a $221 price target and an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

11:20
09/25/17
09/25
11:20
09/25/17
11:20
Periodicals
Amazon acquires '4 Blocks', Deadline Hollywood reports »

Amazon Prime Video…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

11:20
09/25/17
09/25
11:20
09/25/17
11:20
General news
FX Action: USD-JPY »

FX Action: USD-JPY fell…

AAPL

Apple

$151.89

-1.5 (-0.98%)

11:18
09/25/17
09/25
11:18
09/25/17
11:18
Recommendations
Apple analyst commentary  »

Apple iPhone X preorder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

$NSD

NASDAQ Market Internals

11:17
09/25/17
09/25
11:17
09/25/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$151.89

-1.5 (-0.98%)

11:16
09/25/17
09/25
11:16
09/25/17
11:16
Periodicals
Apple's iPhone 8 shows slower adoption than previous models, Localytics reports »

The iPhone 8 and iPhone 8…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

$NYE

NYSE Market Internals

11:16
09/25/17
09/25
11:16
09/25/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
09/25/17
09/25
11:15
09/25/17
11:15
General news
U.S. equities were dented by N. Korean remarks »

U.S. equities were dented…

11:15
09/25/17
09/25
11:15
09/25/17
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
09/25/17
09/25
11:15
09/25/17
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

UN

Unilever; also tag UL

$58.67

0.06 (0.10%)

, UL

Unilever; also tag UN

$57.57

0.13 (0.23%)

11:10
09/25/17
09/25
11:10
09/25/17
11:10
Hot Stocks
Unilever gets into hot South Korean beauty market with acquisition »

Shares of Unilever (UN,…

UN

Unilever; also tag UL

$58.67

0.06 (0.10%)

UL

Unilever; also tag UN

$57.57

0.13 (0.23%)

GS

Goldman Sachs

$230.42

-0.61 (-0.26%)

KHC

Kraft Heinz

$77.52

-1.49 (-1.89%)

EL

Estee Lauder

$107.95

0.365 (0.34%)

LVMUY

LVMH

$55.05

0.208 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

  • 17

    Oct

  • 22

    Oct

UPS

UPS

$117.51

-0.16 (-0.14%)

11:10
09/25/17
09/25
11:10
09/25/17
11:10
Options
Bullish longer-term play in UPS »

Bullish longer-term play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$95.22

-6.895 (-6.75%)

, LH

LabCorp

$150.06

-5.01 (-3.23%)

11:09
09/25/17
09/25
11:09
09/25/17
11:09
Hot Stocks
Medical diagnostics names slide after CMS proposes cuts »

Following the news of the…

DGX

Quest Diagnostics

$95.22

-6.895 (-6.75%)

LH

LabCorp

$150.06

-5.01 (-3.23%)

EXAS

Exact Sciences

$45.96

0.96 (2.13%)

NEO

NeoGenomics

$11.01

0.09 (0.82%)

GHDX

Genomic Health

$30.98

0.13 (0.42%)

VCYT

Veracyte

$8.48

0.18 (2.17%)

VRML

Vermillion

$1.29

0.05 (4.03%)

GNMK

GenMark

$9.52

-0.04 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 30

    Nov

SPY

SPDR S&P 500 ETF Trust

$248.97

-0.47 (-0.19%)

, SPX

S&P 500

11:05
09/25/17
09/25
11:05
09/25/17
11:05
Periodicals
North Korea says firing missiles at U.S 'inevitable,' Guardian says »

According to the…

SPY

SPDR S&P 500 ETF Trust

$248.97

-0.47 (-0.19%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$64.24

-0.09 (-0.14%)

11:05
09/25/17
09/25
11:05
09/25/17
11:05
Options
Carnival call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

CCC

Calgon Carbon

$21.38

-0.025 (-0.12%)

11:04
09/25/17
09/25
11:04
09/25/17
11:04
Downgrade
Calgon Carbon rating change  »

Calgon Carbon downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$35.91

-0.05 (-0.14%)

11:04
09/25/17
09/25
11:04
09/25/17
11:04
Hot Stocks
SpringWorks launches with $103M in Series A funding, rights to 4 programs »

SpringWorks Therapeutics,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 18

    Oct

  • 31

    Oct

  • 08

    Nov

SPX

S&P 500

11:04
09/25/17
09/25
11:04
09/25/17
11:04
General news
North Korea says Trump's comments declaration of war, Bloomberg reports »

North Korean Foreign…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSMT

PriceSmart

$87.60

0.15 (0.17%)

11:04
09/25/17
09/25
11:04
09/25/17
11:04
Initiation
PriceSmart initiated  »

PriceSmart initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

EBS

Emergent BioSolutions

$38.52

0.18 (0.47%)

11:02
09/25/17
09/25
11:02
09/25/17
11:02
Recommendations
Emergent BioSolutions analyst commentary  »

Emergent BioSolutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AIR

AAR Corp.

$37.17

0.23 (0.62%)

10:58
09/25/17
09/25
10:58
09/25/17
10:58
Hot Stocks
AAR Corp. to provide airframe maintenance for Air Canada fleet »

AAR and Air Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNT

Ubiquiti

$54.18

1.52 (2.89%)

10:57
09/25/17
09/25
10:57
09/25/17
10:57
Periodicals
Citron publishes new report on Ubiquiti Networks »

After Citron Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Nov

WFC

Wells Fargo

$54.21

-0.0369 (-0.07%)

10:55
09/25/17
09/25
10:55
09/25/17
10:55
Options
Wells Fargo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

GPC

Genuine Parts

$93.73

5.745 (6.53%)

10:55
09/25/17
09/25
10:55
09/25/17
10:55
Conference/Events
Genuine Parts to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

  • 30

    Oct

SSRM

SSR Mining

$10.26

0.16 (1.58%)

10:52
09/25/17
09/25
10:52
09/25/17
10:52
Upgrade
SSR Mining rating change  »

SSR Mining upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$41.13

0.24 (0.59%)

, SCOR

comScore

$29.10

0.25 (0.87%)

10:50
09/25/17
09/25
10:50
09/25/17
10:50
Periodicals
Nielsen sues comScore to prevent Extended TV service, Reuters reports »

Nielsen Holdings (NLSN)…

NLSN

Nielsen

$41.13

0.24 (0.59%)

SCOR

comScore

$29.10

0.25 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.